Clinical Trial Update: Estrogen Receptor Beta and Mood [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing an estrogen receptor beta–modulating therapy for perimenopause-related depression; results were posted on 2025-09-16.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Estrogen receptor beta modulator (ERβ agonist)

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Perimenopause-Related Depression | Phase 2 | Status: COMPLETED | Results posted: 2025-09-16